Tyra Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Tyra Biosciences, Inc. (TYRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 714.75 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-04
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 712.37K shares, a 240.88% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 2.38K shares, a 99.44% decline year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 76.95K shares, a 71.79% decline year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 261.34K shares.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 968.88K shares, a 233.84% increase from fiscal 2024.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 290.22K shares, a 27.96% decline from fiscal 2023.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 402.86K shares, a 21.53% decline from fiscal 2022.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 513.37K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 712.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 714.75K shares 10-Q · filed 2026-08-04 | 791.70K shares derived: sum of 3 quarters · filed 2026-08-04 | 1.05M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 2.38K shares 10-Q · filed 2026-05-13 | 79.33K shares derived: sum of 2 quarters · filed 2026-05-13 | 340.67K shares derived: sum of 3 quarters · filed 2026-05-13 | 549.65K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 76.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 338.30K shares derived: sum of 2 quarters · filed 2026-03-02 | 547.28K shares derived: sum of 3 quarters · filed 2026-03-02 | 968.88K shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 261.34K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 470.32K shares derived: sum of 2 quarters · filed 2025-11-05 | 891.93K shares 10-Q · filed 2025-11-05 | 1.16M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 208.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 630.59K shares 10-Q · filed 2025-08-14 | 903.42K shares derived: sum of 3 quarters · filed 2025-08-14 | 903.42K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 421.60K shares 10-Q · filed 2025-05-08 | 694.43K shares derived: sum of 2 quarters · filed 2025-05-08 | 694.43K shares derived: sum of 3 quarters · filed 2025-05-08 | 705.66K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 272.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 272.83K shares derived: sum of 2 quarters · filed 2025-03-27 | 284.06K shares derived: sum of 3 quarters · filed 2025-03-27 | 290.22K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 11.23K shares derived: sum of 2 quarters · filed 2024-11-07 | 17.39K shares 10-Q · filed 2024-11-07 | 120.81K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 11.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 17.39K shares 10-Q · filed 2024-08-07 | 120.81K shares derived: sum of 3 quarters · filed 2024-08-07 | 120.81K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 6.16K shares 10-Q · filed 2024-05-09 | 109.58K shares derived: sum of 2 quarters · filed 2024-05-09 | 109.58K shares derived: sum of 3 quarters · filed 2024-05-09 | 200.17K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 103.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 103.42K shares derived: sum of 2 quarters · filed 2024-03-19 | 194.01K shares derived: sum of 3 quarters · filed 2024-03-19 | 402.86K shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 90.59K shares derived: sum of 2 quarters · filed 2023-11-07 | 299.44K shares 10-Q · filed 2023-11-07 | |
| 2023-06-30 | 90.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 299.44K shares 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | 208.85K shares 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | 513.37K shares 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |